期刊
BLOOD
卷 132, 期 12, 页码 924-934出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood.2019001212
关键词
-
类别
资金
- Public Health Service from National Institutes of Health, National Cancer Institute [5U24CA076518]
- National Heart, Lung, and Blood Institute
- National Institute of Allergy and Infectious Diseases
- Health Resources and Services Administration (Department of Health and Human Services) [HHSH250201700006C]
- Office of Naval Research [N0001417-1-2388, N00014-17-1-2850, N00014-18-1-2045]
- Adaptive Biotechnologies
- Amgen, Inc.
- Astellas Pharma US
- Atara Biotherapeutics, Inc.
- Be the Match Foundation
- bluebird bio, Inc.
- Bristol-Myers Squibb Oncology
- Celgene Corporation
- Chimerix, Inc.
- CytoSen Therapeutics, Inc.
- FredHutchinson Cancer Research Center
- Gamida Cell, Ltd.
- Gilead Sciences, Inc.
- HistoGenetics, Inc.
- Immucor
- Incyte Corporation
- Janssen Scientific Affairs, LLC
- Jazz Pharmaceuticals, Inc.
- Karius, Inc.
- Karyopharm Therapeutics, Inc.
- Kite Pharma, Inc.
- Medac, GmbH
- Mediware
- Medical College of Wisconsin
- Merck Co, Inc.
- Mesoblast, MesoScale Diagnostics, Inc.
- Millennium
- Takeda Oncology Co.
- Miltenyi Biotec, Inc.
- Mundipharma EDO
- NMDP
- Novartis Pharmaceuticals Corporation
- PCORI
- Pfizer, Inc.
- Pharmacyclics, LLC
- PIRCHE AG
- Sanofi Genzyme
- Seattle Genetics
- Shire
- Spectrum Pharmaceuticals, Inc.
- St. Baldrick's Foundation
- Swedish Orphan Biovitrum, Inc.
- Takeda Oncology
- University of Minnesota
- National Heart, Lung, and Blood Institute [1U24HL138660]
- National Cancer Institute
Allogeneic hematopoietic cell transplantation involves consideration of both donor and recipient characteristics to guide the selection of a suitable graft. Sufficient high-resolution donor-recipient HLA match is of primary importance in transplantation with adult unrelated donors, using conventional graft-versus-host disease prophylaxis. In cord blood transplantation, optimal unit selection requires consideration of unit quality, cell dose and HLA-match. In this summary, the National Marrow Donor Program (NMDP) and the Center for International Blood and Marrow Transplant Research, jointly with the NMDP Histocompatibility Advisory Group, provide evidence-based guidelines for optimal selection of unrelated donors and cord blood units.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
